FDA Approved: ZANAFLEX — Supplemental Application (Covis Pharma US, Inc)

View source ↗

Summary

The FDA approved a supplemental NDA for ZANAFLEX (tizanidine hydrochloride) submitted by Covis Pharma US, Inc., resulting in updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Spinal Cord Injury

Drugs mentioned

• ZANAFLEX (Tizanidine hydrochloride)

Snippet

SUPPL AP for ZANAFLEX (TIZANIDINE HYDROCHLORIDE)